Stalz C Vilbrun
Overview
Explore the profile of Stalz C Vilbrun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khan U, Rich M, Franke M, Lachenal N, Ahmed S, Bekele A, et al.
Clin Infect Dis
. 2024 Dec;
PMID: 39658125
Background: The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen and six months or longer for Bdq and...
2.
Zeng C, Hernan M, Trevisi L, Sauer S, Mitnick C, Hewison C, et al.
medRxiv
. 2024 Jan;
PMID: 38293100
Rationale: Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resistance. Evidence is needed to inform optimal treatment for these patients. Objectives: We compared...
3.
Khan P, Franke M, Hewison C, Seung K, Huerga H, Atwood S, et al.
Eur Respir J
. 2021 Jun;
59(1).
PMID: 34140298
Background: Recent World Health Organization guidance on drug-resistant tuberculosis treatment de-prioritised injectable agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the...
4.
Ocheretina O, Escuyer V, Mabou M, Royal-Mardi G, Collins S, Vilbrun S, et al.
PLoS One
. 2014 Mar;
9(3):e90569.
PMID: 24599230
The World Health Organization has recommended use of molecular-based tests MTBDRplus and GeneXpert MTB/RIF to diagnose multidrug-resistant tuberculosis in developing and high-burden countries. Both tests are based on detection of...